Law360
ADVERTISEMENT
Hikma Should Face Amarin s Patent Suit, Magistrate Says
Law360 (August 3, 2021, 8:54 PM EDT) Hikma Pharmaceuticals should not be able to dodge a lawsuit claiming it encouraged doctors to prescribe its generic version of the heart drug Vascepa for uses covered by a series of Amarin patents, a Delaware federal magistrate judge says.
Magistrate Judge Jennifer L. Hall on Tuesday issued a report and recommendation in a lawsuit filed by Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Ltd. and Mochida Pharmaceutical Co. Ltd. alleging that Hikma induced infringement of three patents.
Specifically, Amarin alleged in the so-called skinny label case that Hikma induced doctors to infringe the patents by instructing them to use the Hikma generic.
Share:
Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new heart failure requiring hospitalization with higher achieved serum EPA levels
Amarin to Webcast Discussion of Data Presented at ACC.21 Monday, May 17, 2021 at 4:30 p.m., Eastern Time
DUBLIN, Ireland and BRIDGEWATER, N.J., May 15, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of REDUCE-IT
® HEART FAILURE (HF) at ACC.21, the American College of Cardiology s 70th Annual Scientific Session, being held virtually from May 15 – 17, 2021. These new analyses supported by Amarin were presented on behalf of all authors by Deepak L. Bhatt, M.D., M.P.H., Brigham and Women s Hospital, Harvard Medical School, Boston, MA.
To embed, copy and paste the code into your website or blog:
On April 23, 2021, President Biden signed into law two bipartisan bills aimed at reducing prescription drug prices by supporting generic and biosimilar alternatives to branded drugs.
The Ensuring Innovation Act supports generic drugs by clarifying the technical qualifications for earning exclusivity as a new chemical entity. The Advancing Education on Biosimilars Act provides for increased federal efforts to educate patients, doctors and caregivers about biosimilar drugs.
These changes come as proposals for more comprehensive legislation on drug pricing, such as allowing Medicare to negotiate prices directly with manufacturers, have thus far been excluded from the Biden Administration’s major spending initiatives. Below is a short summary of each new bill.
Share:
Commercial Launch of VAZKEPA in Europe on Track to Commence in Q3 2021 Following Recent Market Authorization with VASCEPA® Growth in the United States Positioned to Increase as the Impact of COVID-19 Recedes
Expenses Managed in Q1 2021 to Minimize Operating Loss Despite Revenue Impact of COVID-19 and Other Factors
Management to Host Conference Call Today at 7:30 a.m. ET
DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter ended March 31, 2021 and provided an update on company operations.
Recent Key Amarin Highlights:
Q1 net total revenue
: Net total revenue in the first quarter of 2021 was $142.2 million, consisting of $140.8 million in net product revenue from the United States, $0.5 million in net product revenue from outside the United States and $0.8 million in licensing and royalty revenue. Net product revenue from the United States declined $4.7 million,
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and .
Amarin Corporation plcApril 22, 2021 GMT
VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication
1,2,
VAZKEPA authorization for Great Britain follows recent VAZKEPA authorization for European Union
DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ: AMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Marketing Authorization for VAZKEPA (icosapent ethyl) as a treatment to reduce the risk of cardiovascular events in high cardiovascular risk statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and either established cardiovascular disease or diabetes, and at least one additional cardiovascular risk factor